CNTA | Ticker Profile - Titan Protect

CNTA

Centessa Pharmaceuticals plc

Healthcare · Biotechnology · NMS

$39.62

Data: 2026-05-18

✓ ETHICAL PASS

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.1B

Total market value of the company

Trailing P/E

0.00

Forward P/E

-20.89

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-57.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Centessa Pharmaceuticals plc

Company description not available.

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

1.9% PASS

Debt must be below 33% of total assets

Cash Ratio

4.5% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.545

Excellent risk-adjusted returns

Kelly Fraction

0.1219

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.814

Returns exceed worst-case losses — strong risk profile

Annual Return

123.0%

Historical annualised return based on price data

Max Drawdown

-43.7%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.78

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.24

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-03-26	ANDERSON KAREN M	Officer	41,076	$329,019
2026-03-26	WEINHOFF GREGORY M	Officer	23,998	$92,392
2026-03-26	WEINHOFF GREGORY M	Officer	23,998	$719,940
2026-03-26	ANDERSON KAREN M	Officer	41,076	$1,237,382
2026-03-17	ANDERSON KAREN M	Officer	74,811	$299,992
2026-03-17	ANDERSON KAREN M	Officer	74,811	$2,109,180
2026-03-13	ANDERSON KAREN M	Officer	109,398	$438,686
2026-03-13	ANDERSON KAREN M	Officer	109,398	$436,258
2026-03-13	WEINHOFF GREGORY M	Officer	73,196	$1,927,131
2026-03-13	ANDERSON KAREN M	Officer	120,029	$3,150,673

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-18

Before you go